Table 1 Summary of clinical and pathological features for 16 patients.
Patient | Age at surgery | Menopause (age) | Gravidity/Parity | cStage | cTNM | Histological type | ER | PgR | HER2 | Subtype Classification | Ki-67 labeling index | Neoadjuvant chemotherapies |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P20 | 54 | Post (50) | G3P2 | IIIA | cT1cN2aM0 | * | 0 + 0 | 0 + 0 | 0 | TNBC | 65% | None |
P33 | 35 | Pre | G1P1 | I | cT1cN0M0 | Mucinous | 5 + 2 | 2 + 3 | 1+ | Luminal | 25% | None |
P34 | 82 | Post (50) | G3P3 | I | cT1cN0M0 | IDC | 5 + 2 | 3 + 1 | 0 | Luminal | 20% | None |
P35 | 45 | Pre | G2P1 | I | cT1cN0M0 | IDC | 5 + 3 | 5 + 3 | 0 | Luminal | 3% | None |
P38 | 63 | Post (51) | G2P2 | I | cT1cN0M0 | IDC | 5 + 3 | 5 + 3 | 1+ | Luminal | 8% | None |
P39 | 66 | Post (52) | G3P2 | IIA | cT2N0M0 | ILC | 5 + 3 | 5 + 3 | 1+ | Luminal | 7% | None |
P40 | 46 | Pre | G0P0 | I | cT1cN0M0 | IDC | 5 + 2 | 5 + 2 | 1+ | Luminal | 8% | None |
P41 | 48 | Pre | G1P1 | I | cT1bN0M0 | IDC | 0 + 0 | 0 + 0 | 0 | TNBC | 85% | None |
P44 | 60 | Post (53) | G2P2 | IIA | cT2N0M0 | IDC | 0 + 0 | 0 + 0 | 1+ | TNBC | 80% | None |
P49 | 73 | Post (58) | G0P0 | IIA | cT2N0M0 | IDC | 5 + 3 | 5 + 3 | 2 + ,DISH(-) | Luminal | 15% | None |
P50 | 61 | Post (51) | G1P1 | I | cT1cN0M0 | IDC | 5 + 3 | 0 + 0 | 1+ | Luminal | 10% | None |
P51 | 65 | Post (51) | G3P3 | I | cT1cN0M0 | IDC | 0 + 0 | 2 + 1 | 2 + ,DISH(-) | Luminal | 85% | None |
P52 | 47 | Pre | G3P3 | IIB | cT2N1M0 | ** | 0 + 0 | 0 + 0 | 3+ | HER2 | 65% | CEFx4, DHPx4 |
P54 | 67 | Post (52) | G0P0 | I | cT1bN0M0 | ILC | 5 + 3 | 2 + 2 | 1+ | Luminal | 5% | None |
P64 | 51 | Post (NA) | G3P1 | IIA | cT2N0M0 | Mucinous | 5 + 3 | 5 + 3 | 1+ | Luminal | 20% | None |
P93 | 32 | Pre | G0P0 | IIB | cT2N1M0 | IDC | 4 + 2 | 4 + 3 | 3+ | Luminal-HER2 | 75% | None |
